Nulibry Integral Pharma Solutions EU Limited · Authorised · authorised 15 Sep 2022 · ATC A16AX19
Therapeutic indication (EMA)
Nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
Active substance
Fosdenopterin
- US FDA 1
- EMA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NULIBRY | EQ 9.5MG BASE/VIAL | powder · intravenous | SENTYNL THERAPS INC | Prescription | 26 Feb 2021 |
EMA European Union — centrally authorised medicines
Safety signals and safety-related labeling changes
- US FDA 26 May 2026 NULIBRY — safety-related labeling change
Labeling sections changed: Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.